Summary of Study ST001232
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000825. The data can be accessed directly via it's Project DOI: 10.21228/M81X1W This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001232 |
| Study Title | Combining stage - specificity and metabolomic profiling to advance drug discovery for malaria |
| Study Type | Drug Exposure |
| Study Summary | Metabolic examination/confirmation of MoA stage-specificity observed in study |
| Institute | Pennsylvania State University |
| Department | BMB |
| Laboratory | Llinás Laboratory |
| Last Name | Owen |
| First Name | Edward |
| Address | 6014 Goldenrod Court |
| eso5005@psu.edu | |
| Phone | 8144045235 |
| Submit Date | 2019-07-09 |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-03-03 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001315 |
| Treatment Summary: | Infected Red Blood cells were exposed to Antimalarial Compounds, associated with sample names. No treatment (as in the case of blanks) denotes these samples did not undergo the treatment incubation (blanks are made at the point of extraction in this case), whereas treated with no drug relates that these samples (no drug or ND) underwent the same treatment incubation as other treated samples, but in this case as a negative control with no drug administered. |
| Treatment: | Abiotic |
| Treatment Compound: | Atovaquone, Dihydroartemisinin (DHA), Ferroquin (FQ), GNF-Pf-5660, KAI407, Lumefantrine (LMF), Methylene Blue, MMV00017 (Naphthoquine), MMV000442, MMV00787, MMV007181, MMV019555, MMV020746, MMV021735, MMV022224, MMV022478, MMV027496, MMV030666, MMV085071, MMV665794, MMV665939, MMV667491, MMV668311, MMV675939, Mefloquine (MQ), Piperaquine (PPQ), WLL |
| Treatment Route: | Addition to media |
| Treatment Dose: | 10xIC50 |
| Treatment Dosevolume: | Always less than 10 uL per 5 mL sample |
| Treatment Doseduration: | 2.5 hours |
| Treatment Vehicle: | Stocks kept in either DMSO or Water |
| Cell Storage: | Temperature/Gas Mixture controlled incubator |
| Cell Growth Container: | 6-well plate |
| Cell Growth Config: | 5 mL per well, each with 1x10^8 cells |
| Cell Media: | RPMI 1640 w/ Albumax, Gentamycin, Hypoxanthine, HEPES, Sodium Bicarbonate |
| Cell Harvesting: | PBS Wash followed by 90% methanol extraction |
